NASDAQ:WINT

Windtree Therapeutics Stock Signals

etoro logo Buy WINT
*Your capital is at risk
$0.0580
-0.0070 (-10.77%)
At Close: Nov 17, 2025

Latest Data & Signals Issued

Signal Type Signal Value Data
Score -5.544 15 days ( 42.57 % )
Last Price $0.0580 -10.77 %
High/ Low $0.0580 - $0.0700 11.72%
Chg 7 Days -8.23 % $0.0632 $0.0580
Chg 30 Days -51.87 % $0.121 $0.0580
Chg 12 mos -99.76 % $23.76 $0.0580
Trend - 3 mos -30.25 % Width: 1,144.37 %
Trend - 12 mos -99.82 % Width: 75.44 %
Pred. range - 3 mos $0.0086 - $0.107 -85.21 % - 84.05 %
Pred. range - 12 mos N/A - -$0.0032 -100.00 % - -105.59 %
Short MA avg 3 mos Buy Nov 10, 2025 - 6 days
Long MA avg 3 mos Sell Oct 29, 2025 - 14 days
Short/Long MA avg 3 mos Sell Oct 31, 2025 - 12 days
Short MA avg 12 mos Sell Oct 27, 2025 - 16 days
Long MA avg 12 mos Buy Jul 17, 2025 - 87 days
Short/Long MA avg 12 mos Sell May 13, 2025 - 131 days
Pivot Short Sell Oct 10, 2025 - 27 days
Bollinger Buy Nov 30, -0001 - N/A days
MACD Sell No Dates Stored For This Signal

Signals Effectiveness

Backtesting is not only a way to check stock signal accuracy, but also a tool to continually improvement. Data can be used for self adjustment as each stock has an individual behavior.

Accuracy and return is not the same. A stock signal may provide low statistical accuracy, but the signals may prove high return in average.

Sharp market dips or fundamental changes (earning reports, news updates etc), may force a short term reaction and disturb the signals (Signals may jump quickly from buy to sell, just to return to buy).

Stock Score

Buy Signals
Sell Signals

Bollinger Bands

Buy Signals
Sell Signals

MACD

Buy Signals
Sell Signals

Moving Average (7d)

Buy Signals
Sell Signals
Click to get the best stock tips daily for free!
ABOUT WINDTREE THERAPEUTICS INC
Windtree Therapeutics
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF,...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE